Company Information

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Our proprietary Cabaletta Approach to B cell Ablation (CABA™) platform is designed to provide deep, durable and potentially curative responses with one-time administration, with the possibility of eliminating the need for chronic immune suppressive therapies. The CABA™ platform has potential applicability across dozens of B cell-mediated autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, systemic sclerosis, pemphigus vulgaris and myasthenia gravis. It encompasses both the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach as well as Cabaletta’s proprietary Chimeric AutoAntibody Receptor T (CAART) cells. Our lead CARTA candidate, CABA-201, is a 4-1BB-containing CD19-CAR T cell therapy based on a clinically evaluated fully human CD19 binder with a strong safety profile. CABA-201 is currently under development for autoimmune diseases with high unmet need. Our proprietary CAART cells are designed to selectively bind and eliminate the pathogenic B cells that express disease-causing autoantibodies while sparing normal B cells. Through our CABA™ platform, we have discovered and developed seven product candidates, including our clinical-stage therapies for patients with mucosal pemphigus vulgaris and MuSK myasthenia gravis. We hold multiple agreements with the University of Pennsylvania and other academic institutions to develop engineered T cell therapies. Our goal is to leverage our team’s expertise in autoimmunity and T cell therapy and our network of collaborators to rapidly discover and develop our portfolio of engineered T cell therapy candidates to transform the treatment of autoimmune diseases.